Anna R. H.
- Country
- Poland
- Department
- N/A
Research Overview
- 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis
- J1A-MC-KDAF: A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis
- An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.
Data & Insights
Has run more than one trial at 239 of 494 partner sites.
Specializations
Inflammatory Arthritis
Clinical research in psoriatic arthritis, rheumatoid arthritis, and axial spondyloarthritis with a strong focus on symptom control, joint inflammation, and functional improvement in chronic musculoskeletal diseases.
- Psoriatic arthritis
- Rheumatoid arthritis
- Axial spondyloarthritis
Work in this area also extends to broader arthritis and joint diseases, reflecting involvement across multiple rheumatic diseases.
Autoimmune Connective Tissue Disease
Research activity includes systemic lupus erythematosus, Sjögren's disease, and related connective tissue diseases, with emphasis on immune-mediated disease activity and persistent systemic symptoms.
- Systemic lupus erythematosus
- Sjögren's disease
- Connective tissue diseases
This portfolio also includes immune system diseases and broader autoimmune diseases that require targeted immunomodulatory care.
Psoriasis and Immune-Mediated Skin Disease
Clinical interest includes moderate to severe plaque psoriasis and its overlap with inflammatory joint disease, supporting research at the interface of dermatologic and rheumatologic immune pathology.
- Moderate to severe plaque psoriasis
- Psoriatic arthritis overlap
- Immune-mediated skin disease
The therapeutic scope reflects attention to persistent cutaneous inflammation alongside systemic disease burden.
Biologic and Targeted Immunotherapy
The trial portfolio is centered on biologic therapies and targeted immunotherapies for chronic inflammatory disease, including agents directed at cytokine pathways, immune cell signaling, and inflammatory mediators.
- Biologic therapies
- Targeted immunotherapies
- Inflammatory mediator pathways
These studies align with treatment areas in rheumatic diseases and autoimmune disorders requiring advanced immune modulation.
Long-Term Safety and Clinical Tolerability
Research also covers the safety, tolerability, and sustained clinical use of therapies in chronic inflammatory conditions, with attention to ongoing disease management and treatment durability.
- Long-term safety
- Tolerability
- Chronic disease management
This area supports therapeutic decision-making across musculoskeletal and autoimmune indications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.